Background
Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by the pathological aggregation of α-synuclein, leading to severe motor and autonomic dysfunction. Currently, there are no disease-modifying therapies, creating a significant unmet medical need. The AMULET trial investigated amlenetug, a monoclonal antibody targeting aggregated α-synuclein, as a potential treatment to slow disease progression.
